The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

På svenska

Author

  • PA Broliden
  • IM Dahl
  • R Hast
  • Bertil Johansson
  • E Juvonen
  • L Kjeldsen
  • A Porwit-MacDonald
  • M Sjoo
  • JM Tangen
  • B Uggla
  • G Oberg
  • E Hellstrom-Lindberg
Show all

Summary, in English

The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.

Publishing year

2006

Language

English

Pages

667-670

Publication/Series

Haematologica

Volume

91

Issue

5

Document type

Journal article

Publisher

Ferrata Storti Foundation

Topic

  • Hematology

Keywords

  • cyclosporine A
  • MDS
  • ATG
  • treatment

Status

Published

ISBN/ISSN/Other

  • ISSN: 1592-8721